Ribociclib added to endocrine therapy extends survival in postmenopausal patients with metastatic breast cancer

A study led by researchers from The University of Texas MD Anderson Cancer Center showed a significant overall survival benefit with ribociclib plus endocrine therapy for postmenopausal patients with hormone receptor-positive (HR+) human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer. This is the first demonstration of a survival advantage with a front-line CDK4/6…

Read more

This website is using cookies to improve the user-friendliness. You agree by using the website further.

Privacy policy
Skip to content